X0306 4 2022-09-16 1 0001537917 TYME TECHNOLOGIES, INC. TYME 0001295391 Michels Douglas A C/O TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY - SUITE 103 BEDMINSTER NJ 07921 1 0 0 0 Common Stock 2022-09-16 4 D 0 110000 D 0 D Director Stock Option - Option to buy 2.71 2022-09-16 4 D 0 45833 D 2028-10-01 Common Stock 45833 0 D Director Stock Option - Option to buy 2.71 2022-09-16 4 D 0 100000 D 2028-10-01 Common Stock 100000 0 D Director Stock Option - Option to buy 1.18 2022-09-16 4 D 0 50000 D 2029-08-22 Common Stock 50000 0 D Director Stock Option - Option to buy 1.22 2022-09-16 4 D 0 65000 D 2030-08-19 Common Stock 65000 0 D Director Stock Option - Option to buy 1.10 2022-09-16 4 D 0 88000 D 2031-08-23 Common Stock 88000 0 D Director Stock Option - Option to buy 0.31 2022-09-16 4 D 0 88000 D 2032-08-23 Common Stock 88000 0 D Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 4,820 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,008 shares of Syros common stock for $61.84 per share, after giving effect to the Reverse Split. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 4,382 shares of Syros common stock for $61.84 per share, after giving effect to the Reverse Split. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split. By: /s/ Richard Cunningham as attorney-in-fact for Douglas A Michels 2022-09-16